All
Immunotherapy Combination Shows Benefit in Phase 2 Advanced Melanoma Trial
April 25th 2016The combination of Yervoy and Opdivo showed a 42 percent improvement in overall survival compared with Yervoy monotherapy for patients with advanced melanoma in a two-year assessment of the phase 2 CheckMate-069 trial.
More Than Campbell's Sister: On Siblings and Cancer
April 18th 2016"Although the patients are super important, the siblings are just as important and play a crucial role in their brother or sister’s fight. Time and time again, I found myself telling my sister’s story when I was asked to share my story."